Page last updated: 2024-11-13

pepbs1-ac peptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AP301 peptide: a synthetic peptide mimicking the lectin-like domain of TNF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91864495
MeSH IDM0512145

Synonyms (11)

Synonym
solnatide [inn]
solnatide
ap-301
tip-peptide
ap301 peptide
cys-gly-gln-arg-glu-thr-pro-glu-gly-ala-glu-ala-lys-pro-trp-tyr-cys cyclic (1->17)-disulfide
l-cysteine, l-cysteinylglycyl-l-glutaminyl-l-arginyl-l-alpha-glutamyl-l-threonyl-l-prolyl-l-alpha-glutamylglycyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-lysyl-l-prolyl-l-tryptophyl-l-tyrosyl-, cyclic (1->17)-disulfide
unii-17zs80333g
259206-53-6
17zs80333g ,
EX-A7494

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Serial assessments included spirometry, exhaled nitric oxide (eNO), vital signs, ECG, safety laboratory, adverse events (AE), and blood samples for the quantification of AP301 in plasma."( A FIM study to assess safety and exposure of inhaled single doses of AP301-A specific ENaC channel activator for the treatment of acute lung injury.
Eder, S; Fischer, B; Fischer, H; Hermann, R; Lucas, R; Mascher, H; Pietschmann, H; Schwameis, R; Tzotzos, S; Zeitlinger, M, 2014
)
0.4
" A novel inhaled peptide agent (AP301, solnatide) was shown to markedly reduce pulmonary edema in animal models of ARDS and to be safe to administer to healthy humans in a Phase I clinical trial."( Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS-a randomized, placebo-controlled, double-blind trial.
Fischer, B; Frank, S; Kranke, P; Kredel, M; Krenn, K; Lucas, R; Markstaller, K; Meybohm, P; Schmid, B; Ullrich, R; ZwiƟler, B, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (69.23)24.3611
2020's4 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.77 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (23.08%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (69.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]